PHS164 Trends In Medicare Part D Medication Therapy Management Eligibility Criteria  by Qin, Y. et al.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  A153
Medicare MTM eligibility criteria. The Medicare MTM eligibility criteria need to be 
modified in order to eliminate their disparity implications.
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Objectives: To examine racial and ethnic disparities in health status, health ser-
vices utilizations and costs, and medication utilization based on Medicare medi-
cation therapy management (MTM) eligibility status. Greater disparities among 
MTM-ineligible than MTM-eligible individuals would suggest that MTM eligibility 
criteria have the potential to exacerbate racial and ethnic disparities in health out-
comes. MethOds: This is a retrospective cross-sectional analysis of the Medicare 
Current Beneficiary Survey (2007-2008). A difference-in-differences model was used 
by including in regression models interaction terms between dummy variables for, 
e.g., non-Hispanic Blacks and MTM eligibility criteria, when examining racial dis-
parities. Both main and sensitivity analyses were conducted to represent the ranges 
of the MTM eligibility thresholds used by insurance plans in 2010. The interaction 
term was interpreted on both the multiplicative term and the additive term. Various 
regression models were used. Results: Whites were more likely to report self-
perceived good health status than Blacks and Hispanics among both MTM-eligible 
and MTM-ineligible populations. Disparities were greater among MTM-ineligible 
than MTM-eligible populations (e.g., on additive term, difference in odds= 1.94 and 
P< 0.01 for Whites and Blacks; difference in odds= 2.86 and P< 0.01 for Whites and 
Hispanics in main analysis). When examining racial disparities, activities of daily 
living, instrumental activities of daily living, and generic possession ratio produced 
similar findings. Whites had a higher number of physician visits than Hispanics 
and the disparities were greater among the MTM-ineligible than MTM-eligible 
individuals (incidence rate ratio= 1.40; P< 0.01). Analyses on chronic conditions, 
costs of physician visits, hospitalizations, and total health care costs produced 
similar patterns on ethnic disparities. No other variables exhibited significant find-
ings. cOnclusiOns: Current MTM eligibility criteria may potentially aggravate 
existing racial and ethnic disparities in health services utilization and costs and 
medication utilization measures. Future research should examine strategies to 
remediate the effects of MTM eligibility criteria on racial and ethnic disparities.
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Objectives: To understanding the clinical care pathway and patient character-
istics of those patient visits that use the catheterization laboratory (cath lab) but 
do not result in a percutaneous coronary intervention (PCI) and/or coronary artery 
bypass surgery (CABG) procedure shortly thereafter. The target population is those 
patient visits that are outpatient and elective, rather than those coming in through 
the emergency room, or inpatient admissions. MethOds: The Premier hospital 
database from July 1, 2011 through June 30, 2012 was utilized as the data source. 
This database contains complete patient billing, hospital cost, and coding histo-
ries from more than 600 hospitals and ambulatory facilities throughout the United 
States. Eligible patients were > age 45 at the time of the coronary angiography 
visit, and must have had one of the following primary diagnosis of Atherosclerosis 
or chest pain using the International Classification, 9th Revision (ICD-9): 414.01, 
786.5, or 786.59. Patient visits with a diagnosis code(s) for myocardial infarction or 
stroke/trans-ischemic attack were excluded. Patients that died during the visit were 
excluded as well. Results: Of 354,790 coronary angiography visits identified, 68,026 
visits (19.2%) met the inclusion criteria. Only 7% of patient visits (4,788) resulted in 
a return visit within 60 days for a PCI (29%), CABG (71%), or both (< 1%). Less than 2% 
(81) came back to the hospital through the ER. Total median coronary angiography 
cost per visit for the group of interest was $2,565, with the cardiology department 
accounting for 57% ($1,470) of costs. Left heart cardiac catheterization was the most 
common procedure (86%). cOnclusiOns: There appears to be a substantial popu-
lation receiving elective coronary angiography, with no immediate action resulting 
from that visit. Technologies that could enable another clinical pathway to avoid the 
cath lab and an invasive procedure may lead to lower hospital costs.
PHS168
effect of inPatient adMiSSionS on tReatMent RegiMenS in PatientS 
WitH tyPe 2 diabeteS
Ellis J.J.1, Bouchard J.R.2, Saundankar V.1, Baltz J.3, Meah Y.3, Moretz C.1
1Comprehensive Health Insights, Louisville, KY, USA, 2Novo Nordisk, Inc., Plainsboro, NJ, USA, 
3Humana Inc., Louisville, KY, USA
Objectives: Inpatient admissions may represent an important opportunity for the 
review and revision of treatment regimens of type 2 diabetes mellitus (T2DM) patients. 
This retrospective study seeks to assess the impact of inpatient admissions on modi-
fication of T2DM pharmacotherapy regimens. MethOds: A retrospective cohort of 
Humana Medicare Advantage Prescription Drug (MAPD) and commercial patients 
with T2DM with at least one inpatient stay between January 2007 and December 2012 
was identified (IPH group). The date of first inpatient hospitalization was defined 
as the index date. Patients with at least 12 months of continuous eligibility pre-
index and post-index were identified. A non-inpatient admission comparison group 
(non-IPH group) of T2DM patients was propensity score-matched on age, gender, 
plan enrollment and diabetes complication score. The primary outcome of interest 
was treatment modification, defined as an addition, switch or discontinuation of an 
anti-diabetic drug class within 10 days post-discharge. Results: The study cohort 
comprised 34,624 patients with T2DM (17,312 matched pairs). The IPH group had 
Objectives: Ontario (ON) and Québec (QC), the two largest provinces in Canada, 
have public programmes for immunization against influenza. We aimed at reviewing 
and presenting differences and similarities between the two provinces, and identi-
fying resources allocated to respective programmes. MethOds: Government and 
health professions information sites (medicine, nursing, pharmacy) were searched, 
as well as the grey literature, supplemented by direct communication with health 
care professionals. Resources (professional services and materials) were identified 
and listed, considering both Ministry of Health and patient perspectives. Results: 
Major differences were identified in both eligibility of patients and provision of flu 
shots (FS). QC limits the FS to the elderly (60 years or older), infants (6-23 months) 
and persons “at risk” (persons with chronic conditions, living in isolated communi-
ties, health care workers, caregivers and those travelling to endemic areas). ON has a 
universal programme covering the entire population except infants (under 6 months 
of age) and persons in whom the vaccine is contraindicated. In QC, FS are admin-
istered mainly by public health nurses and physicians, while in ON, FS can also be 
injected by trained and certified pharmacists (for persons 5 years of age and older). 
ON Pharmacies where FS are administered can directly bill the Ministry of Health 
for an honorarium for each injection. There are also differences between rural and 
urban areas with regard to eligibility in the case of QC and possibly access to FS in 
both provinces. cOnclusiOns: The ON programme is more comprehensive than 
the QC programme, both by expanded population eligibility and through increased 
availability of resources by making FS available at certified pharmacies. This work 
will prepare the ground for a future comparative economic analysis.
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Objectives: To describe trends in eligibility thresholds of Medicare medication 
therapy management (MTM) services to identify patterns that may hinder eligi-
bility/enrollment. MTM Services were established in 2006 as part of the Medicare 
outpatient prescription drug (Part D) benefit. MTM eligibility was based on number 
of chronic conditions, Part D medications, and total drug costs. To increase MTM 
enrollment rate, the Centers for Medicare and Medicaid Services (CMS) lowered the 
allowable eligibility thresholds to at or below 3 for number of chronic diseases and 
at or below 8 for Part D drugs, and drug cost threshold from $4,000 to $3,000 in 2010. 
However, an increase in MTM enrollment rates has not been seen. MethOds: This 
study analyzed data extracted from the Medicare Part D MTM Programs Fact Sheets 
published on the cms.gov website. Fact Sheets for 2008-2013 were used to search 
for changes and trends over time that may potentially affect the enrollment rate 
for Medicare beneficiaries. These years were the only ones available from the cms.
gov website. Results: In 2008, 48.7% plans opened MTM enrollment to patients 
with only two chronic disease states, while the other half restricted enrollment 
to patients with a minimum number of three to five chronic disease states. Data 
for years 2011-2013 indicate that approximately 20% of plans opened enrollment 
to patients with 2 chronic disease states, with the remaining 80% restricting 
enrollment to patients with 3 or more chronic diseases. The trends for both 
Medicare Advantage plans and independent Part D plans were similar. CMS pol-
icy change in 2010 is also correlated with increase proportion of plans set their 
eligibility threshold at 8 part D drugs, the maximum number allowa-
ble. cOnclusiOns: Changes to the eligibility thresholds may have been barriers 
for increased MTM enrollment. CMS needs to find alternative strategies to increase 
MTM enrollment.
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Objectives: To determine whether the implementation of the Medicare Part D in 
2006 was associated with changes in differential racial and ethnic disparity pat-
terns between the individuals ineligible for medication therapy management (MTM) 
services and MTM-eligible individuals. If Part D implementation is not associated 
with reductions in greater racial and ethnic disparities in MTM-ineligible than the 
MTM-eligible individuals, the urgency for modifying MTM eligibility criteria would 
be even increased. MethOds: Data from the Medicare Current Beneficiary Survey 
were analyzed. A generalized difference-in-differences analyses, difference-in-dif-
ferences-in-differences-in-differences (DDDD) model, was used to examine changes 
in difference in disparities between the MTM-ineligible and MTM-eligible individu-
als from 2004-2005 to 2007-2008 in relation to the changes from 2001-2002 to 2004-
2005. Disparities were examined in health outcomes, health services utilizations/
costs, and medication utilization patterns. MTM eligibility criteria for 2010 were 
examined and both main and sensitivity analyses were conducted to represent the 
ranges of the MTM eligibility thresholds used by insurance plans. Various regression 
models varied according to the type of dependent variables. Results: The main 
analysis found no significant DDDD values. For racial disparities, according to some 
sensitivity analyses, Part D implementation was associated with a reduction in 
greater racial disparities among the MTM-ineligible and MTM-eligible individuals 
in activities of daily living (DDDD= 1.13; P= 0.03 for one analysis) and instrumental 
activities of daily living (DDDD= 0.95; P= 0.03 for one analysis). For ethnic disparities, 
Part D implementation was associated with reduction in any greater disparities 
among the MTM-ineligible than MTM-eligible individuals in costs of physician vis-
its (DDDD= -4613.71; P= 0.04 for one analysis) and high risk medication utilization 
(DDDD= -0.10; P= 0.03 for one analysis). cOnclusiOns: Part D implementation is 
not consistently associated with reductions in the disparity implications of the 
